Gajdos M, Cagán S, Spustová V, Dzúrik R
Klinika farmakoterapie Ustavu preventívnej a klinickej medicíny v Bratislave, Slovakia.
Bratisl Lek Listy. 1996 Jul;97(7):382-7.
Atherosclerosis is a complex progressive process with high morbidity and frequent dramatic mortality. The experience from the developed countries justifies the effectiveness of atherosclerosis prevention. The combination of nonpharmacologic, antiaggregatory and antihyperlipemic prevention reaches currently the effectiveness of surgical intervention, with the exception of sudden events. On the other hand the surgical intervention does not restore the process of atherosclerosis and requires the same secondary prevention if the long term prognosis is to be improved. The review presents the guidelines on nonpharmacologic, antihyperlipemic (up to the combination of statin with fibrates) and the antiaggregatory prevention with the initial dose of ASA being 200 mg and a long term dose being > or = 30 mg of ASA/d treatment. (Tab. 4, Fig. 3, Ref. 25.)
动脉粥样硬化是一个复杂的渐进过程，发病率高且常常导致严重的死亡率。发达国家的经验证明了动脉粥样硬化预防措施的有效性。目前，非药物、抗血小板和降血脂预防措施相结合，除了突发情况外，已达到手术干预的效果。另一方面，手术干预并不能逆转动脉粥样硬化进程，若要改善长期预后，仍需要同样的二级预防措施。本文综述了非药物、降血脂（直至他汀类药物与贝特类药物联合使用）以及抗血小板预防的指南，其中阿司匹林的初始剂量为200毫克，长期剂量为每日≥30毫克。（表4，图3，参考文献25）
